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Abstract: Bisphosphonates are the most widely prescribed treatment for postmenopausal 
osteoporosis, secondary osteoporosis, and male osteoporosis. Notwithstanding their high 
effectiveness and favorable safety profile, the adherence to bisphosphonate treatment remains 
low. Different treatment strategies aim to improve the clinical effectiveness of bisphosphonate 
therapy. This review paper assesses the clinical utility of oral intermittent risedronate in the 
treatment of postmenopausal osteoporosis. The new delayed-release risedronate formulation 
is a safer and easy to use alternative to other risedronate therapy. Oral risedronate, a potent 
nitrogen-containing bisphosphonate, has been extensively studied using daily regimens. A new 
intermittent (weekly) dosing regimen confirmed its clinical effectiveness in relation to vertebral 
and nonvertebral fracture prevention. The absence of significant differences in the incidence of 
adverse effects confirmed the favorable tolerability of the weekly dosage. In efforts to improve 
patient adherence to treatment, an innovative, delayed-release formulation of risedronate, which 
ensures adequate bioavailability of the active compound when taken with food, was introduced. 
The once-weekly delayed-release formulation of risedronate proved to be noninferior to the 
daily dosage of risedronate in terms of bone mineral density and markers of bone turnover. 
In addition, the incidence of new morphometric vertebral fractures was comparable in both 
treatment regimens. The new delayed-release formulation of risedronate showed a favorable 
safety profile. Delayed-release risedronate is a promising, new, effective, and convenient 
alternative to current bisphosphonate treatments. It appears to allow better patient adherence 
to antiresorptive treatment.
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Introduction
Osteoporosis has been recognized as a debilitating disease since the mid 1990s.1 The 
most common type is postmenopausal osteoporosis, but osteoporosis secondary to 
disease or drug use is not infrequent. The major consequences of osteoporosis are 
low-trauma fractures, which seriously impact patients’ quality of life, mortality, and 
are a costly burden to the healthcare system. One in two women and one in four men 
above the age of 50 years will suffer an osteoporotic fracture. Data from the Dubbo 
Osteoporosis Epidemiology Study, in which women and men aged 60 years and over 
were followed up for up to 15 years, showed that the mortality-adjusted residual 
lifetime fracture risk is 44% for women and 25% for men.2 Fractures were associated 
with increased morbidity and mortality.3
Fortunately, powerful and reliable diagnostic and therapeutic tools are available 
to fight the “silent epidemic” of osteoporotic fractures. Bisphosphonates, selective 
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estrogen receptor modulators, strontium ranelate, calcitonin, 
teriparatide, and estrogens are all used for the prevention or 
treatment of osteoporosis.
Oral bisphosphonates are the most widely prescribed 
antiresorptive treatment in postmenopausal osteoporosis, 
secondary osteoporosis, and male osteoporosis. They 
are effective in reducing the incidence of vertebral and 
nonvertebral osteoporotic fractures. Their effects are 
manifested relatively early (6–12 months after onset of 
treatment) and are prolonged. In efforts to improve patient 
compliance, bisphosphonates are applied in different modes 
of administration: daily, weekly, and monthly oral dosages, 
as well as intravenous formulations.
Alendronate, risedronate, and ibandronate are three oral 
formulations that have been used in clinical practice for 
nearly two decades. Various well designed, randomized 
control studies have shown their high effectiveness and 
favorable safety profile in treatment of postmenopausal 
osteoporosis. Alendronate significantly reduces the risk of 
hip, vertebral, and other clinical fractures at three years with 
more pronounced effects in women with postmenopausal 
osteoporosis.4,5 Risedronate reduces the incidence of vertebral 
and nonvertebral fractures in 3 years by 49% and 39%, 
respectively.6 It also significantly reduces the risk of hip 
fractures in elderly women with osteoporosis.7 Oral daily 
and intermittent ibandronate have been shown to significantly 
reduce the incidence of clinical vertebral fractures in 3 years.8 
However, due to poor patient adherence to treatment, clinical 
effectiveness with bisphosphonates is suboptimal.
This  paper  reviews  the  different  modalities  of 
administration of risedronate and their utility from a 
clinician’s and patient’s point of view. A literature search in 
the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed) 
was performed and the following keywords were used: 
risedronate, clinical utility, patient considerations, patient 
preferences. Only good quality articles were selected 
such as double-blind randomized controlled trials (by the 
authors’ discretion). The review is not systematic in the 
way meta-analyses such as the one published by Cranney 
et al are.9 It reviews the use of delayed-release risedronate 
in the light of the current developments of patient-friendly 
formulations. New delayed-release risedronate allows for 
a dosing regimen independent of food and drink intake 
with adequate bioavailability and pharmacological activity. 
It provides an answer to the major patient considerations 
regarding the efficacy, safety, tolerability, and simplicity of 
bisphosphonate use.
Risedronate for the prevention  
of postmenopausal osteoporosis
Risedronate was initially applied in oral daily doses of 
5 mg. The large Vertebral Efficacy with Risedronate 
Therapy (VERT) studies, VERT-North America and 
VERT-multinational, demonstrated that in women with 
postmenopausal osteoporosis risedronate leads to an increase 
in bone mineral density (BMD) and a reduction in vertebral 
and nonvertebral fractures.6,10 Risedronate was shown to 
increase BMD in the lumbar spine by approximately 6.0% 
and by 1.6%–3.1% in the femoral neck.6,10 In the VERT-North 
America trial risedronate reduced the incidence of vertebral 
fractures by 65% in the first year and by 49% in 3 years 
along with a decrease of nonvertebral fractures by 39% in 3 
years. The Hip Intervention Program trial was a randomized 
controlled trial with hip fracture incidence as the primary 
outcome.7 Risedronate was found to prevent hip fractures in 
the elderly (70–79 years) with osteoporosis, with a relative 
fracture risk of 0.6% over 2 years compared to a placebo 
(95% confidence interval 0.4–0.9, P = 0.009).7 Prolonged 
treatment with risedronate was also shown to be effective. 
A 6–7-year long extension study showed a significant 
reduction of fractures in the placebo group, which was then 
given active treatment with risedronate. The incidence of 
vertebral fractures was 7.4% and 6.0% for the placebo group 
put on risedronate and the original risedronate only group, 
respectively, during the sixth and seventh year.11 A large 
Cochrane meta-analysis of 5 mg daily doses of risedronate 
confirmed the high efficacy in preventing vertebral, 
nonvertebral, and hip fractures, along with increased safety 
and tolerability.12 These results were further confirmed by 
the large meta-analysis by Cranney et al.9
Adherence to treatment  
with oral bisphosphonates
Pharmacological fracture prevention requires patient 
adherence to the prescribed dosing regimen of osteoporosis 
treatment. Adherence is suboptimal in all chronic diseases 
and this is the case in osteoporosis. When medication is not 
taken in accordance with the prescribed regimen, altered 
benefits or elevated additional risks can be observed. 
Patient adherence to treatment is usually met by compliance 
and persistence. The definitions for compliance and 
persistence were developed by the International Society for 
Pharmacoeconomics and Outcomes Research Medication 
Compliance and Persistence Work Group.13 Compliance is 
measured over a certain period of time and represents the 
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percentage of doses taken as prescribed. Persistence refers to 
the act of continuing the treatment regimen for the prescribed 
period of time. It may be defined as “the duration of time from 
initiation to discontinuation of therapy.”13 Clinical effects of 
treatment should be measured against patient’s adherence to 
treatment (ie, how well patients take their medication and 
for how long).
Although the efficacy and safety of bisphosphonates have 
been proven beyond doubt, patient compliance and persistence 
remain poor. This is partly due to patients’ concerns about 
drug-related side effects (mainly gastrointestinal), patients’ 
lack of understanding or motivation, the asymptomatic 
nature of osteoporosis, and the inconvenient, complex dosing 
regimens. Another recent concern is the exaggerated fear of 
atypical fractures caused by the bisphosphonate itself.14 The 
administration requirements for oral bisphosphonates, such 
as risedronate, include taking the medication on an empty 
stomach after an overnight fast with 200–250 mL of water in 
the upright position and waiting for at least 30 minutes before 
taking regular meals, other drugs, or beverages. However, due 
to this inconvenience, a large proportion of patients on oral 
bisphosphonates (33.5% in Ettinger et al’s study) do not wait 
for the minimum of 30 minutes before initiating eating after 
dosing.15 In addition, oral bisphosphonates are contraindicated 
in patients with swallowing problems or gastroesophageal 
reflux.16 However, the gastrointestinal safety of risedronate 
has been confirmed in a pooled analysis of nine studies.17 
Upper gastrointestinal tract side effects are experienced in 
29.6% of the patients taking a placebo compared to 29.8% in 
the patients taking risedronate. Endoscopic studies conducted 
on a large patient sample show no significant differences 
among the treatment groups.17 Unfortunately, the fear of 
upper gastrointestinal side effects associated with the daily 
regimen is one of the major reasons preventing patients from 
taking the drug properly. New formulations replacing the 
need for daily intake are well accepted by patients.
Clinical trials with intermittent oral 
risedronate
Risedronate remains active on the bone surface for an 
extended period of time, which has led to the production 
of new formulations of risedronate with extended dosing 
intervals. The so-called “bridging concept” was then applied. 
This concept allows one to take advantage of the efficacy of 
the new, extended formulation of the bioavailability and the 
effect on the fracture risk surrogates, such as increasing BMD 
and suppressing bone marker levels, which are comparable 
with those of the daily formulation. Based on this concept 
the weekly dosage of risedronate is not inferior to the daily 
dosage in terms of BMD and markers of bone turnover.18 
In addition, the incidence of new morphometric vertebral 
fractures is comparable in both treatment regimens. The 
efficacy and tolerability of risedronate once weekly compared 
to risedronate once daily have been further confirmed in a 
randomized double-blind 2-year study.19 During treatment 
with 5 mg risedronate daily and 35 mg risedronate weekly, 
the incidence of new vertebral fractures was 2.9% and 1.5%, 
respectively, along with an incidence of nonvertebral fractures 
reported as adverse events (5.0% and 4.9%, respectively).19 
No significant differences have been observed in the serious 
adverse events or gastrointestinal side effects rate. However, 
the convenience of risedronate application has been greatly 
improved with once-weekly dosing.
It was assumed that less frequent treatment intervals 
are conducive to better patient acceptance and compliance. 
Despite the introduction of weekly bisphosphonates, a high 
percentage of women are not optimally compliant with their 
osteoporosis treatment.20 It is reassuring that those women 
on weekly bisphosphonates have higher rates of compliance 
and persistence than those on daily regimens, but even they 
fall below the acceptable levels.20 Data from large retail phar-
macy databases has also confirmed the higher adherence to 
therapy among patients on weekly versus daily therapy.21 This 
knowledge inevitably led to the development of less frequent 
dosing regimens. Monthly dosing of 75 mg risedronate on 
two consecutive days in a month has been compared to 5 mg 
risedronate taken daily.22 Mean percent changes in lumbar 
spine BMD (3.4% versus 3.6%) and bone turnover markers 
are significant and comparable in both treatment groups. Both 
treatments are safe and generally well tolerated.22 Similarly, 
a monthly regimen of risedronate 50 mg taken on three 
consecutive days each month has BMD and bone turnover 
effects, in addition to a good safety profile, that are similar 
to those of 5 mg of risedronate taken daily.23 This study 
was, however, not powered enough to detect noninferiority; 
therefore, future studies will be needed to examine this aspect 
of the treatment.
A Phase II, 6-month dose-ranging study compared the 
effects of monthly and daily risedronate in postmenopausal 
osteoporosis patients.24 Three monthly doses were tested – 100, 
150, and 200 mg. The three doses proved to be equally safe 
and efficacious. However the 150 mg monthly regimen is the 
one that most closely matched the 5 mg daily treatment.24 The 
efficacy and safety of the 150 mg risedronate once-monthly 
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formulation was shown in a 2-year double-blinded study.25 
The mean change from baseline in lumbar spine BMD was 
3.4% in the 5 mg per day group and 3.5% in the 150 mg 
once monthly group. The mean percent changes of BMD in 
the hip and in the suppression of bone markers were similar 
in both treatment regimens. The same was true for the 
incidence of adverse events, such as upper gastrointestinal 
tract reactions.25
A summary of the major studies illustrating the different 
administration schemes of risedronate is shown in Table 1.
Patient considerations with use  
of oral bisphosphonates
Bisphosphonate efficacy, tolerability, and safety   profile have 
been demonstrated in numerous clinical trials.   However, 
  compliance and persistence with antiresorptive treatments 
remain low. As a consequence, fracture   prevention is not 
effective and is more costly. In a recent study, Halpern 
et al showed that patients with low (medication possession 
ratio ,50%) versus high (medication possession ratio $80%) 
adherence had a 37% higher risk of fracture.26 In the 
same patients, low adherence was associated with 12% 
higher all-cause medical costs and 59% more all-cause 
hospitalizations. Even once-monthly regimens cannot ensure 
100% compliance with osteoporotic treatment. A few studies 
have shown that compliance with once-monthly bisphospho-
nates is suboptimal and 1-year persistence is very close to 
that of weekly bisphosphonates.27 This is probably due to the 
fact that this approach cannot totally eliminate the patients’ 
concerns. Generally, concerns are based on one’s view of 
the efficacy of the medication, the severity of their illness, 
and their ability to control it with medication. In the case of 
bisphosphonates, there are particular patients’ concerns due 
to the need to take risedronate on an empty stomach with 
plain water and remain in the upright position for at least 
30 minutes thereafter. Some of the problems associated with 
these requirements include:
1.  A great number of patients are taking multiple medications. 
A particular difficulty arises when other medications must 
be taken on an empty stomach such as levothyroxine or 
antihypertensive drugs.
2.  Some of the patients are accustomed to doing their 
  prescribed regular physical exercise just before breakfast. 
Many of them are concerned that they might provoke 
esophageal reflux and upper gastrointestinal adverse 
events.
3.  Many of the patients with osteoporosis are suffering from 
anxiety or have multiple obsessive fears. One example 
is the fear of going out because falls and fractures might 
occur. There are many patients who feel that something 
might go wrong even when taking the bisphosphonate in 
the proper way. This is especially true when they want 
to go on vacations and travel to distant locations.
4.  A few of the very old patients experience difficulties in 
following complex instructions due to dementia or other 
psychogenic or neurogenic conditions.
Studies focusing on patients’ nonadherence have shown 
that it might lead to insufficient suppression of bone resorption, 
lack of sufficient BMD increase, and, more importantly, to 
diminished or no antifracture efficacy.28,29 Many patients 
Table 1 The selected studies illustrating the different administration schemes of risedronate – data on fracture risk surrogates are 
presented
Authors Number of 
participants 
completing  
the study
Study 
duration
Comparator to  
the 5 mg daily  
dosage
Spine BMD  
increase
Bone  
markers
Main conclusion
Harris  
et al19
1127 2 years 35 and 50 mg  
once weekly
5.17%, 4.74%, and  
5.47% for the 5 mg,  
35 mg, and 50 mg  
subgroups
Similar based  
on analysis  
of variance
Once-weekly doses are comparable 
in efficacy and safety to the 5 mg 
daily dose
Delmas  
et al22
1229 1 year 75 mg on two 
consecutive  
days monthly
3.4% versus 3.6% Similar in  
both groups
75 mg on two consecutive days  
was not inferior in efficacy and 
safety versus 5 mg daily
Racewicz  
et al23
98 6 months 50 mg on three 
consecutive  
days monthly
3.22% versus 3.42% Similar in  
both groups
50 mg on three consecutive days 
was similar to 5 mg daily with 
respect to suppressing bone 
turnover and increasing BMD
Delmas  
et al25
1094 1 year 150 mg once  
monthly
3.4% versus 3.5% Similar in  
both groups
150 mg once monthly is similar  
in efficacy and safety to daily dosing
Abbreviation: BMD, bone mineral density.
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perceive the requirement to take risedronate on an empty 
stomach as inconvenient. In a study with alendronate, 33.5% 
of patients stated that they were unable to or did not wait for 
30 minutes before taking their breakfast.15 The major problem 
with this is the decreased absorption of bisphosphonates in 
the presence of food. Pharmacokinetic studies have reported 
very low bioavailability if bisphosphonates are taken in the 
prandial or postprandial state.30,31 In a study conducted on 
nursing home residents, the deviation from proper taking of 
the bisphosphonate was reflected by the lack of suppression 
of bone turnover markers.32 In another study the response of 
lumbar spine BMD to treatment was smaller (only 1.5% at 
month six) if risedronate was taken between or after meals, 
rather than when taken properly at least 30 minutes before 
breakfast (2.9% increase in BMD at month six).33 Therefore, 
the instruction “before food or drink” might compromise the 
clinical benefit of the bisphosphonates.
One approach to overcome these difficulties is to use an 
intravenous route of administration. The intravenous formu-
lations must, however, be applied by medical personnel. They 
are more costly and might be accompanied by a higher rate 
of adverse reactions, such as the flu-like syndrome.34
The concept of delayed-release 
bisphosphonates
Bisphosphonates strongly chelate polyvalent cations 
(mostly calcium and magnesium) from food. Consequently, 
absorption of oral bisphosphonates is severely inhibited 
in the presence of food. There are now more restrictions 
when taking risedronate prior to the first food or drink in 
the morning while adequate bioavailability is guaranteed. 
Novel approaches to overcome the “30–60 minutes before 
food or drink” requirement are in the form of newly 
developed enteric-coated 35 mg risedronate tablets. They 
help risedronate to reach the duodenum and jejunum where 
substances that interfere with its absorption are scarce. The 
new formulation contains an additional chelating agent that 
binds cations (such as calcium) which may compromise 
the absorption of risedronate. This is a promising approach 
in light of the high percentage of patients who are not 
complying with the “30–60 minutes before food or drink” 
requirement.
The effectiveness of this new delayed-release 35 mg 
risedronate formulation, which can be taken with or without 
food, was tested against the 5 mg daily risedronate dose in a 
Phase III international study.35 Nine hundred and twenty-two 
women were randomized to either take a 5 mg daily dose or a 
35 mg weekly dose at least 30 minutes before or immediately 
after breakfast. Noninferiority was tested in mean percent 
change in lumbar spine BMD (measured by dual-energy 
X-ray absorptiometry) and suppression of bone turnover 
markers. The incidence of vertebral fractures was assessed 
by semiquantitative morphometric analysis. The least square 
mean percent change from baseline in lumbar spine BMD 
at week 52 was found to be 3.3% in the 35 mg taken after 
breakfast weekly group and 3.1% in the 5 mg daily group. 
Additionally, significant increases in BMD in all regions 
of the hip were also noted, with no significant differences 
between the classical and novel regimens (Figure 1). 
According to this finding, the novel 35 mg delayed-release 
risedronate tablet taken just after breakfast is not inferior to 
the classical 5 mg daily risedronate dose. The bone turnover 
markers were suppressed in all treatment groups (Figure 2). 
Surprisingly, reductions in urinary N-terminal telopeptide/
creatinine and serum C-terminal telopeptide levels were 
significantly greater in the novel 35 mg risedronate after 
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Figure 1 Mean percent changes from baseline in lumbar spine and total hip bone mineral density in women receiving 5 mg risedronate daily ( ), 35 mg slow-release 
risedronate once weekly 30 minutes after breakfast ( ), and 35 mg slow-release risedronate before breakfast ( ). 
Reproduced with permission from McClung et al.35
Abbreviation: SE, standard error of the mean.
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breakfast regimen than with the 5 mg daily dosage. The 
authors suggested a slightly better bioavailability of the 
new formulation as a plausible explanation for this finding. 
The incidence of new morphometric vertebral fractures 
was very low and the study was not extensive enough to 
allow for comparisons. The adverse event profile was very 
similar in all treatment groups. However, in comparing the 
35 mg before breakfast and 35 mg after breakfast regimens, 
there was an observed trend for higher incidences of upper 
absorptiometry tract adverse effects (P = 0.004). All of 
these events were mild to moderate. In conclusion, the novel 
formulation of 35 mg risedronate taken after breakfast shows 
similar efficacy and safety as the 5 mg daily dosage or the 
35 mg before breakfast formulation. It can, therefore, reduce 
the impact of food ingestion on compliance of osteoporosis 
patients through increased drug bioavailability and clinical 
utility.35 Future studies will have to determine whether the 
upright position is necessary for drug administration and 
what a reasonable time interval is for binding to calcium 
tablets and other cations.
This novel approach remains to be tested in male osteopo-
rosis patients as risedronate is one of the few drugs which has 
been extensively tested and is indicated for this condition.36,37 
It would be of interest to compare enteric-coated weekly 
risedronate tablets with the 150 mg once-monthly formula-
tion, which may be preferred by patients.38–40
Clinical utility of bisphosphonates
Clinical utility measures “cost” in relation to outcomes. It 
provides important information to help make choices between 
different treatments. Various studies have demonstrated the 
clinical effectiveness of bisphosphonates in preventing osteo-
porotic fractures and increasing bone mineral content.4–10,12,43 
However, fracture reduction should be accomplished with 
a cost-effective therapy. Analyses of cost-effectiveness 
provide important information to healthcare providers who 
seek to allocate scarce resources with maximum effective-
ness on a population level. Oral bisphosphonates have been 
in clinical use for treatment of osteoporosis for nearly two 
decades. However, fracture rates and associated medical 
costs remain high. Moreover, differences in the effective-
ness of these drugs have not been investigated due to lack 
of head-to-head comparative, randomized controlled trials of 
oral bisphosphonates. Various randomized controlled trials 
provide evidence for reduction of fracture rates (vertebral and 
nonvertebral) with alendronate and risedronate. However, 
only ibandronate reduces the rate of vertebral fractures. 
The major challenge that health care providers face today 
is in reducing fracture risks through cost-effective therapy. 
Several studies investigate the clinical utility of the three 
most commonly used oral bisphosphonates (alendronate, 
risedronate, and ibandronate).41–43
In a large observational database analysis, cost, 
adherence, fracture risk, and total health care utilization 
were  assessed  in  a  population  treated  with  oral 
bisphosphonates (alendronate, risedronate, and ibandronate).41 
The authors reported low adherence to oral bisphosphonates 
measured by medication possession ratio (range 0.44–0.58). 
During the study period of 36 months, the adherence 
rate for the three bisphosphonates dropped continuously. 
Although there was significantly lowered medication 
possession ratio with ibandronate at 24 months (ibandronate 
taken once monthly), the authors concluded that the rate of 
adherence in the study could be considered to be similar for 
all three bisphosponates.41 When considering fracture risk, 
there were no significant differences between risedronate, 
alendronate, and ibandronate. A cost comparison among 
the three oral bisphosphonates determined that patients on 
ibandronate had higher treatment-related costs than those 
using alendronate or risedronate. However, the adjusted 
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Figure 2 Mean percent changes from baseline in bone markers in women receiving 5 mg risedronate daily ( ), 35 mg slow-release risedronate once weekly 30 minutes 
after breakfast ( ), and 35 mg slow-release risedronate before breakfast ( ). 
Reproduced with permission from McClung et al.35
Abbreviations: BAP, bone alkaline phosphatase; Cr, creatinine; NTX, N-terminal telopeptide; SE, standard error of the mean.
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difference among the three study groups was insignificant, 
which suggests that other factors may explain the observed 
cost difference.41 Similarly, there was no significant difference 
in adjusted fracture risk between risedronate-treated patients 
and alendronate or ibandronate users.
In the study by Tosteson et al, risedronate appeared to 
have the most favorable cost-effectiveness profile compared 
to alternative osteoporosis therapy (alendronate, ibandronate, 
parathyroid hormone.42
The difference in methodology makes it difficult to com-
pare results from various studies. The lack of head-to-head 
comparisons in clinical trials of bisphosphonates does not 
provide a valid basis for utility evaluation. Moreover, con-
clusions drawn from studies with a relatively short duration 
(12–18 months) might add biases in a chronic disease such 
as osteoporosis.41
Conclusion
Multidimensional decisions about the usefulness, benefits, 
and drawbacks of particular bisphosphonates influence 
physicians’ decisions in the treatment of osteoporosis. 
Factors such as cost, insurance coverage, physician and 
patient considerations, as well as alternative medications 
may influence decisions concerning osteoporotic treatment. 
Usually, the considerations in the decision-making process are 
effectiveness and/or cost-effectiveness. There is an ongoing 
debate about the clinical utility of different bisphosphonates. 
Many factors should be considered when choosing a treatment 
for postmenopausal osteoporosis, especially the treatment’s 
clinical effectiveness, safety profile, patient adherence, and 
cost-effectiveness. This review provides additional insights 
into the effectiveness of oral bisphosphonates in terms of 
patient adherence, fracture rates, and treatment costs. Oral 
delayed-release 35 mg risedronate administered once weekly 
is not inferior to the classical 5 mg daily risedronate dosing 
regimen. The new intermittent formulation of risedronate 
suppresses bone turnover markers, significantly increases 
BMD, shows low incidence of new morphometric vertebral 
fractures, and is well tolerated in the treatment of osteoporosis 
in postmenopausal women.
Patients’ perspectives, which greatly influence adherence 
to a particular treatment, are usually ignored. A different 
approach is tested with the delayed-release 35 mg rise-
dronate to improve patients’ compliance with antiresorp-
tive therapy and to increase its efficacy in clinical practice. 
The new formulation, which is taken once weekly after 
breakfast, is a promising therapy for postmenopausal osteo-
porosis with respect to patient adherence to treatment and 
subsequent effectiveness of risedronate in clinical practice. 
Continuous efforts aimed at lowering direct and indirect 
health care costs, and proper selection of patients at risk for 
osteoporotic   fractures will improve the clinical utility of oral 
bisphosphonates in preventing osteoporotic fractures.
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